2017 Annual Report

Letter from the CEO

Read

Letter from the CEO

Read

Our mission is to develop therapies that restore function and improve the lives of people with neurological disorders.

The trademarks in the Acorda Therapeutics, Inc. 2017 Annual Report are owned by Acorda Therapeutics, Inc. or its subsidiaries, with the exception of ZANAFLEX CAPSULES owned by Covis Pharma B.V. and SELINCRO owned by H. Lundbeck A/S. ©2018 Acorda Therapeutics, Inc. All rights reserved.